title: Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
abstract: Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.
authors.affiliation: From the Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; and Department of Internal Medicine, Creighton University Medical Center, and Department of Internal Medicine, Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
authors.forename: Smith
authors.initials: S
authors.lastname: Giri
authors.affiliation: From the Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; and Department of Internal Medicine, Creighton University Medical Center, and Department of Internal Medicine, Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
authors.forename: Shadi
authors.initials: S
authors.lastname: Hamdeh
authors.affiliation: From the Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; and Department of Internal Medicine, Creighton University Medical Center, and Department of Internal Medicine, Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
authors.forename: Vijaya Raj
authors.initials: VR
authors.lastname: Bhatt
authors.affiliation: From the Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee; and Department of Internal Medicine, Creighton University Medical Center, and Department of Internal Medicine, Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
authors.forename: James K
authors.initials: JK
authors.lastname: Schwarz
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D020440:Gene Duplication; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009154:Mutation; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D000077157:Sorafenib; D020080:Tandem Repeat Sequences; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; D051941:fms-Like Tyrosine Kinase 3